Market Research Logo

Septic Shock - Pipeline Review, H2 2016

Septic Shock - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Septic Shock - Pipeline Review, H2 2016’, provides an overview of the Septic Shock pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Septic Shock, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Septic Shock and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Septic Shock
    • The report reviews pipeline therapeutics for Septic Shock by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Septic Shock therapeutics and enlists all their major and minor projects
    • The report assesses Septic Shock therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Septic Shock
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Septic Shock
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Septic Shock Overview
    Therapeutics Development
    Pipeline Products for Septic Shock - Overview
    Pipeline Products for Septic Shock - Comparative Analysis
    Septic Shock - Therapeutics under Development by Companies
    Septic Shock - Therapeutics under Investigation by Universities/Institutes
    Septic Shock - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Septic Shock - Products under Development by Companies
    Septic Shock - Products under Investigation by Universities/Institutes
    Septic Shock - Companies Involved in Therapeutics Development
    Adrenomed AG
    Ferring International Center S.A.
    Huons Co., Ltd.
    InflaRx GmbH
    Inotrem S.A.
    Lixte Biotechnology Holdings, Inc.
    Noxxon Pharma AG
    Octapharma AG
    Orion Oyj
    Peptinov SAS
    Pharmazz, Inc.
    Spider Biotech
    Takeda Pharmaceutical Company Limited
    Therashock, LLC
    ViiV Healthcare Limited
    XImmune AB
    Septic Shock - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    3K3A-APC - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    adrecizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AM-12 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Aspidasept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BC-1215 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMS-936559 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BTZO-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug for Sepsis and Septic Shock - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HBN-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HBN-3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HBN-4 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HU-003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IFX-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    L-257 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LB-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    levosimendan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    M-6229 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Motrem - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NOXD-21 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PMZ-2010 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pooled plasma (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Proteins to Inhibit Nuclear Factor Kappa B for Septic Shock - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    R-190 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SB-056 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    selepressin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit TNF-Alpha for Septic Shock - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SP-14 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SP-9 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Septic Shock - Dormant Projects
    Septic Shock - Discontinued Products
    Septic Shock - Product Development Milestones
    Featured News & Press Releases
    Sep 13, 2016: Inotrem Successfully Completes Its First Phase I Clinical Trial with Motrem, a TREM-1 Pathway Modulator for the Treatment of Septic Shock
    Jun 07, 2016: InflaRx initiates phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients undergoing complex cardiac surgery
    Jan 28, 2016: InflaRx announces positive phase IIa top-line results from the SCIENS trial investigating IFX-1, a first-in-class anti-complement C5a antibody
    Oct 08, 2015: Tenax Therapeutics Provides Clinical Update for Lead Candidate Levosimendan
    Jun 16, 2015: Tenax Therapeutics Highlights New Scientific Publication Regarding the Potential Mortality Benefits of Levosimendan in Septic Shock Patients
    Jan 02, 2013: Adrenomed Develops New Drug To Reduce Mortality From Septic Shock
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Septic Shock, H2 2016
    Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Septic Shock - Pipeline by Adrenomed AG, H2 2016
    Septic Shock - Pipeline by Ferring International Center S.A., H2 2016
    Septic Shock - Pipeline by Huons Co., Ltd., H2 2016
    Septic Shock - Pipeline by InflaRx GmbH, H2 2016
    Septic Shock - Pipeline by Inotrem S.A., H2 2016
    Septic Shock - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016
    Septic Shock - Pipeline by Noxxon Pharma AG, H2 2016
    Septic Shock - Pipeline by Octapharma AG, H2 2016
    Septic Shock - Pipeline by Orion Oyj, H2 2016
    Septic Shock - Pipeline by Peptinov SAS, H2 2016
    Septic Shock - Pipeline by Pharmazz, Inc., H2 2016
    Septic Shock - Pipeline by Spider Biotech, H2 2016
    Septic Shock - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
    Septic Shock - Pipeline by Therashock, LLC, H2 2016
    Septic Shock - Pipeline by ViiV Healthcare Limited, H2 2016
    Septic Shock - Pipeline by XImmune AB, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Septic Shock - Dormant Projects, H2 2016
    Septic Shock - Dormant Projects (Contd..1), H2 2016
    Septic Shock - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Septic Shock, H2 2016
    Number of Products under Development for Septic Shock - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report